Ingrid Patsch, MD
Family Medicine · Tucson, AZNPI 1184673279
Payments from drug & device makers
Across 34 payments — averaging $24.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$134
- AbbVie$93
- Amgen$82
- Alkermes, Inc.$72
- Sumitomo Pharma America, Inc.$51
- Lilly USA, LLC$50
- plus $355 from 12 others
What the payments were for
- Food & beverage$837100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $134 |
| AbbVie | 5 | $93 |
| Amgen | 4 | $82 |
| Alkermes, Inc. | 1 | $72 |
| Sumitomo Pharma America, Inc. | 2 | $51 |
| Lilly USA, LLC | 2 | $50 |
| Aimmune Therapeutics, Inc. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Exact Sciences | 2 | $40 |
| Boehringer Ingelheim | 2 | $39 |
| GSK | 2 | $38 |
| Astellas Pharma US Inc | 1 | $27 |
| AstraZeneca | 2 | $27 |
| CSL Behring | 1 | $24 |
| Baxter Healthcare | 1 | $21 |
| Abbott | 1 | $20 |
| Corcept Therapeutics | 1 | $14 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AJOVY$134
How this compares
$837 in reported general payments places this provider in the 65th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 26 | $464 |
| Losartan Potassium | 33 | $348 |
| Amlodipine Besylate | 51 | $341 |
| Atorvastatin Calcium | 49 | $319 |
| Simvastatin | 20 | $264 |
| Levothyroxine Sodium | 28 | $250 |
| Gabapentin | 13 | $179 |
| Metformin Hcl | 21 | $125 |
| Metoprolol Succinate | 15 | $98 |
| Trazodone Hcl | 15 | $91 |
| Hydrochlorothiazide | 16 | $66 |
| Lisinopril | 16 | $64 |
| Alendronate Sodium | 13 | $60 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Tucson
- Dena PetersenTucson$14.7M
- John McGettiganTucson$8.3M
- Kevin PoundsTucson$1.9M
- Thili KulatilakeTucson$1.8M
- Judith BrownTucson$399K
- Hannah LeslieTucson$228K
- Charles MichieliTucson$111K
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.